Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer.
The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients.
Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets.
Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities.
MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.
Company Details
- Employees
- 44
- Founded
- -
- Address
- Wagistrasse 27, Schlieren,zurich 8952,switzerland
- Phone
- +41 44 515 91 40
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- memo-therapeutics.com
- Keywords
- Therapeutic antibodies, Infectious disease, Human antibodies, Antibody repertoire, antibodyome, High throughput, single B cell, Antibody discovery.
- HQ
- Schlieren, Zurich
Memo Therapeutics Ag Questions
Memo Therapeutics Ag's helpline number is +41 44 515 91 40
Memo Therapeutics Ag's website is memo-therapeutics.com
Memo Therapeutics Ag's LinkedIn profile is https://ch.linkedin.com/company/memo-therapeutics-ag
Memo Therapeutics Ag has
44 employees.
View email and phone details for 44
employees at Memo Therapeutics Ag.
Memo Therapeutics Ag's industry is
Biotechnology Research
Memo Therapeutics Ag's top competitors are
Immunos Therapeutics Ag,
Haya Therapeutics,
Tolremo Therapeutics,
Alentis Therapeutics,
Molecular Partners,
Biognosys,
Numab Therapeutics Ag,
Cutiss Ag,
Cdr-Life Inc.,
Araris Biotech Ag.
Memo Therapeutics Ag's support email address is info@memo-therapeutics.com
Memo Therapeutics Ag's categories are Biotechnology Research
Memo Therapeutics Ag's founding year is 2012
